Drug Trial Radar · NCT06315608
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
Last checked: Nov 20, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Jan 1, 2026
Study completion Mar 1, 2026
Sponsor
- Lead sponsor
- MedRegen LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expected to receive 18 injections over the span of 3 months.
Conditions
- Amyotrophic Lateral Sclerosis
- Lou Gehrig Disease
- Motor Neuron Disease
- Motor Neuron Atrophy
Interventions
MRG-001Drug
MRG-001 is a clear liquid solution for subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of Treatment-Emergent Adverse EventsTime frame: 3 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.